AcuCort AB (publ) (XSAT:ACUC)

Market Cap	163.41M +51.0%
Revenue (ttm)	6.68M -13.4%
Net Income	-26.19M
EPS	-0.22
Shares Out	234.44M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	544,431
Average Volume	927,770
Open	0.7270
Previous Close	0.7260
Day's Range	0.6830 - 0.7790
52-Week Range	0.5000 - 0.9700
Beta	1.52
RSI	35.59
Earnings Date	Feb 20, 2026

About AcuCort AB

AcuCort AB (publ) operates as a pharmaceutical company. It offers Zeqmelit, an oral film containing the glucocorticoid dexamethasone for the treatment of acute allergic reactions, croup in children, nausea and vomiting associated with chemotherapy, and for the treatment of patients with COVID-19 who experience respiratory difficulties and require oxygen therapy. The company was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 4
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: ACUC

Financial Performance

In 2025, AcuCort AB's revenue was 6.68 million, a decrease of -13.40% compared to the previous year's 7.72 million. Losses were -26.19 million, 50.5% more than in 2024.